| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 8.155 | 114.143 | 15.264 | 50.695 | 10.281 | 11.348 | 53.723 | 44.347 | 40.875 | 32.199 |
| Total Income - EUR | 8.155 | 114.143 | 15.264 | 50.713 | 10.381 | 11.412 | 55.017 | 44.534 | 40.897 | 32.199 |
| Total Expenses - EUR | 4.122 | 89.574 | 11.677 | 43.748 | 11.141 | 14.989 | 28.047 | 24.697 | 39.029 | 27.396 |
| Gross Profit/Loss - EUR | 4.033 | 24.569 | 3.587 | 6.966 | -760 | -3.576 | 26.970 | 19.837 | 1.868 | 4.803 |
| Net Profit/Loss - EUR | 3.788 | 22.922 | 3.086 | 6.458 | -864 | -3.690 | 26.431 | 19.401 | 1.520 | 4.541 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Friedman Laboratories Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 112 | 886 | 457 | 141 | 0 | 117 | 92 | 77 | 13 | 21 |
| Current Assets | 6.270 | 26.455 | 23.237 | 21.882 | 20.925 | 9.842 | 27.659 | 24.492 | 29.420 | 14.256 |
| Inventories | 974 | 371 | 1.230 | 499 | 2.472 | 2.911 | 4.035 | 3.499 | 4.621 | 2.700 |
| Receivables | 3.167 | 14.075 | 10.586 | 8.837 | 8.628 | 443 | 4.976 | 694 | 739 | 735 |
| Cash | 2.128 | 12.009 | 11.421 | 12.547 | 9.825 | 6.487 | 18.648 | 20.299 | 24.060 | 10.821 |
| Shareholders Funds | 54 | 20.892 | 19.231 | 17.053 | 16.157 | 4.633 | 143 | 19.544 | 21.004 | 4.601 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 6.327 | 6.449 | 4.477 | 4.970 | 4.768 | 5.403 | 29.556 | 5.026 | 8.429 | 9.676 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4617 - 4617" | |||||||||
| CAEN Financial Year |
4617
|
|||||||||
Comments - Friedman Laboratories Srl